Edition:
United States

Bayer AG (BAYZF.PK)

BAYZF.PK on OTC Markets Group

107.65USD
--
Change (% chg)

$0.00 (+0.00%)
Prev Close
$107.65
Open
--
Day's High
--
Day's Low
--
Volume
36
Avg. Vol
8,242
52-wk High
$124.65
52-wk Low
$91.73

Latest Key Developments (Source: Significant Developments)

Bayer says Regorafenib granted priority review in Japan
Friday, 20 Jan 2017 02:02am EST 

Bayer AG : Bayer says Regorafenib from Bayer granted priority review in Japan for the second-line treatment of liver cancer Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Bayer, Leica Biosystems to develop companion diagnostic test for cancer patients
Wednesday, 21 Dec 2016 02:38am EST 

Bayer AG : Says develops companion diagnostic test for cancer patients together with Leica Biosystems . The partners will use Leica Biosystems expertise in assay development, regulatory approval and commercialization of companion diagnostic tests .Financial terms of the agreement were not disclosed.  Full Article

Bayer announces FDA acceptance of supplemental biologics license application for Mybetaapp and Betaconnect navigator
Wednesday, 14 Dec 2016 12:18pm EST 

Bayer:Bayer announces fda acceptance of supplemental biologics license application for mybetaapp and betaconnect navigator.  Full Article

Bayer buys U.S. animal health products from Boehringer
Wednesday, 7 Dec 2016 11:05am EST 

Bayer AG : Says Boehringer Ingelheim Vetmedica, Inc. and Bayer enter into agreement for purchase of U.S. Cydectin® product portfolio . Says to acquire Boehringer's Cydectin bovine and ovine endectocide products in United States .Says the sale of Boehringer's U.S. Cydectin products is a required step toward its acquisition of Merial as part of a swap transaction with Sanofi.  Full Article

Monsanto provides update on Bayer merger
Tuesday, 22 Nov 2016 06:04am EST 

Bayer Ag : Monsanto co - in connection with merger with Bayer, a purported class action lawsuit, captioned ken gawrych, was filed on nov. 16, 2016 . Monsanto- complaint asserts board breached fiduciary duties by agreeing to deal not adequately reflecting co's true value to obtain personal benefits .Monsanto- complaint seeks to enjoin the consummation of the merger; monsanto believes the claims asserted in lawsuit are without merit.  Full Article

Germany's Bayer mandatory convertible bond issue covered - source
Tuesday, 15 Nov 2016 01:26pm EST 

Germany's Bayer : 4 billion euro mandatory convertible bond issue covered - source (Reporting by Dasha Afanasieva).  Full Article

Bayer CEO makes case for U.S.-EU trade after Trump win
Wednesday, 9 Nov 2016 08:02am EST 

Bayer Chief Executive Werner Baumann, commenting on Donald Trump's U.S. presidential election victory:. "After an intense election campaign, the new U.S. president is facing important challenges. For example, it is now important to further strengthen the partnership between the U.S. and the EU. The expansion of our trade relations is of crucial importance for prosperity on both sides of the Atlantic." .. "Another focus should be to develop the healthcare system in the U.S. in a way that gives more patients access to new and innovative therapies." .. The German drugs and chemicals group has global interests, including a big U.S. business, and has agreed to buy U.S. seeds company Monsanto for $66 billion. [nL8N1BQ365] (Reporting by Ben Hirschler; Editing by Adrian Croft) ((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net)) Keywords: USA ELECTION/BAYER.  Full Article

FDA concludes Xarelto clinical trial results not affected by Alere's INRatio
Tuesday, 11 Oct 2016 12:41pm EDT 

U.S. FDA: Analyses conclude that Xarelto clinical trial results were not affected by Alere's faulty monitoring device INRatio .FDA concludes blood thinner drug Xarelto is a safe and effective alternative to warfarin in patients with atrial fibrillation.  Full Article

Monsanto Q4 Loss Per Share of $0.44 on an as-reported basis
Wednesday, 5 Oct 2016 09:10am EDT 

Monsanto Co : Continued Soybean Technology Expansion And Cost Discipline Expected To Drive Return To EPS Growth In FY17 . Initial Steps Underway To Close On Deal With Bayer To Unlock Value For Shareowners . Continued Soybean Technology Expansion And Cost Discipline Expected To Drive Return To Eps Growth In Fy17 . Q4 Earnings Per Share View $-0.03, Revenue View $2.36 Billion -- Thomson Reuters I/B/E/S . Company Reiterated Confidence In Timelines To Close Deal With Bayer By End Of Calendar Year 2017 . In 2017, Company Expects Agricultural Productivity Segment To Deliver $900 Million To $1 Billion Of Gross Profit . In Soybeans, Greater Than 20 Percent Growth In Gross Profit, Coupled With Margin Improvement, Is Expected Year-Over-Year In Fiscal 2017 . Operating Expenses In 2017 Expected To More Than Offset Savings From Restructuring And Cost-Savings Plans . Sees FY 2017 Earnings Per Share $3.83 To $4.35 . Sees As-Reported FY17 EPS Guidance At $3.83 To $4.35 And Ongoing EPS Guidance At $4.50 To $4.90 . Qtrly Net Sales $2,562 Million Versus $2,355 Million Last Year . For Q4, Company Reported $0.44 Loss Per Share On An As-Reported Basis . For Q4, Company Reported $0.07 Earnings Per Share On An Ongoing Basis . Qtrly Ongoing EPS Results Were Better Than Fiscal Year 2015, Driven By $157 Million Gain From Formation Of Sorghum Joint Venture With Remington . FY2017 Earnings Per Share View $4.91, Revenue View $13.83 Billion -- Thomson Reuters I/B/E/S.  Full Article

Bayer receives EU approval for new five-year contraceptive
Tuesday, 4 Oct 2016 04:06am EDT 

Bayer AG : Receives green light for new five-year contraceptive in EU Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

BRIEF-Bayer says Regorafenib granted priority review in Japan

* Bayer says Regorafenib from Bayer granted priority review in Japan for the second-line treatment of liver cancer Further company coverage: